SCHEMBL6460545

SCHEMBL6460545

COC(C)Oc1ccc(F)cc1B(O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TUBB4A P04350 4/20 0.33
TUBB P07437 4/20 0.33
TUBA3C P0DPH7 4/20 0.33
TUBA1B P68363 4/20 0.33
TUBA4A P68366 4/20 0.33
TUBB4B P68371 4/20 0.33
TUBB3 Q13509 4/20 0.33
TUBB2A Q13885 4/20 0.33
TUBB8 Q3ZCM7 4/20 0.33
TUBA3E Q6PEY2 4/20 0.33
TUBA1A Q71U36 4/20 0.33
TUBA1C Q9BQE3 4/20 0.33
TUBB6 Q9BUF5 4/20 0.33
TUBB2B Q9BVA1 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264985 0.86 ACLY (0.39) ENPP2MEN1MAPTHPGDKMT2A
SCHEMBL29952656 0.82 HTT (0.36) ENPP2MEN1MAPTHPGDKMT2A
SCHEMBL15010805 0.82 HTT (0.36) ENPP2MEN1MAPTHPGDKMT2A
SCHEMBL29957287 0.80 MCHR1 (0.36) MEN1MAPTHPGDKMT2AL3MBTL1
SCHEMBL31040152 0.80 ENPP2 (0.57) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4572 0.80 ENPP2 (0.57) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29958018 0.79 HPGD (0.35) ENPP2MEN1MAPTHPGDKMT2A
SCHEMBL24192641 0.77 SLC6A4 (0.39) MEN1MAPTHPGDKMT2AL3MBTL1
SCHEMBL17007971 0.75 MAPT (0.33) MEN1MAPTHPGDKMT2AL3MBTL1
SCHEMBL17007969 0.75 MAPT (0.33) MEN1MAPTHPGDKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050203094-A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors AXYS PHARMACEUTICALS, INC. 2005-09-15 US disclosed
EP-1474400-A1 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-11-10 EP disclosed
WO-2003068756-A1 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203094-A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors F7, HABP2, F13B ENPP2 239/4885MEN1 1556/4885MAPT 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.